Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.
Sarah L. Spitznogle, PharmD*
Advertisement
Articles by Sarah L. Spitznogle, PharmD*
Advertisement
Latest Updated Articles
- Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens
Published: October 14th 2019 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Ethiopia Investigates Marburg Virus Disease Outbreak
2
Top Infectious Disease News Stories Week of November 22 - November 28
3
Scynexis Collaborates With Hackensack Meridian CDI, Johns Hopkins to Develop Therapeutics for Drug-Resistant Fungal Infections
4
Cefiderocol Shows Activity Against Difficult-to-Treat Pathogens
5
